LabCorp’s $6.1 Billion Deal Doesn’t Pass the Test by ROBERT CYRAN

By ROBERT CYRAN

The strategic logic behind the acquisition of clinical trial outsourcing company is hazy, contends Robert Cyran of Reuters Breakingviews.

Published: November 3, 2014 at 12:00AM

from NYT Business Day http://ift.tt/1uk8VgY

from WordPress http://ift.tt/1GgnMwK

via Hadi Aboukhater